Company
Theolytics is developing next‑generation, systemically deliverable oncolytic immunotherapies engineered to achieve meaningful clinical benefit for patients with cancers of high unmet need.
Our Mission
Transforming the Role of Oncolytic Immunotherapies in Cancer Care
Theolytics is committed to unlocking the full therapeutic potential of oncolytic adenoviruses. By combining deep virology expertise with high‑resolution discovery platforms and translational rigor, we design candidates optimised for systemic administration and clinically relevant outcomes.
Our mission is to bring forward therapies that not only demonstrate potent tumour selectivity and activity, but that integrate seamlessly into patient‑centred oncology care.
Our Approach
From Library to Life Discovery with patients at the core
Our Adenovo™ discovery engine interrogates and refines vast libraries of viral variants against clinically relevant human models, allowing us to identify candidates with real‑world therapeutic promise.
We prioritise attributes that matter clinically — selective replication, systemic stability, tissue tropism, manufacturability and immune interplay — to generate oncolytic adenoviruses tailored for specific patient populations.
This disciplined, data‑first approach enables us to translate complex viral biology into therapies with clear mechanisms and compelling paths to the clinic.
